Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

any intends to submit an abstract to the European Association for the Study of the Liver (EASL) to present antiviral and safety data from all three dose levels at the EASL Annual Meeting in late April.
  • 14-day Healthy Volunteer Study. In order to extend the pharmacokinetic and safety profile of ANA598, Anadys has initiated a 14-day study of ANA598 in healthy volunteers, in which subjects will receive ANA598 at dose levels of 400 mg, 800 mg, 1200 mg once-daily (QD) and 600 mg twice-daily. Enrollment of the 400 mg cohort is complete, and Anadys expects to receive the data from the full study in the second quarter of 2009.
  • Safety and PK Results for ANA598 in Healthy Volunteers. Single-dose safety and pharmacokinetic results from a Phase I study of ANA598 in healthy volunteers at doses ranging from 400 to 3000 mg were reported at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in November 2008. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. Preclinical results for ANA598 were also reported at AASLD, including data demonstrating that the in vitro virology profile of ANA598 strongly supports clinical exploration of ANA598 in combination with interferon-alpha and with direct antivirals now in development, including protease inhibitors and nucleoside polymerase inhibitors.
  • Long-Term Chronic Toxicology Studies of ANA598. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598 comprised of a 6-month study in rats and a 9-month study in monkeys, as well as embedded 3-month arms in both species. Anadys expects to receive full results from the 3-month arms by the end of the first quarter of 2009.
  • ANA773

    ANA773 is an oral prodrug of a small molecule inducer of endogenous interferons that acts via the to
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine news :

    1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
    2. Anadys Pharmaceuticals to Present at Bio Investor Forum
    3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
    4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
    5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
    6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
    7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
    8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
    9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
    11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... The Little Gym of Houston will attend the ... at Discovery Green in downtown Houston. The eleven ... Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire and their ... to be attending and performing at the Family Fun ... Sugarland-Missouri City location. “We believe in the message and ...
    (Date:7/25/2014)... ON (PRWEB) July 25, 2014 Art of ... providing services to those in Toronto who are looking for ... a study done by the American Academy of Facial ... of 2014, interest in facial plastic surgery showed a surprising ... jobs rose 10 percent, while hair transplants increased by 7 ...
    (Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
    (Date:7/25/2014)... Phoenix, AZ (PRWEB) July 25, 2014 ... firm offering discount attorney’s fees with regard to ... Hastings provide a wide range of legal services ... of the negligence of another individual or corporation. Free ... of determining the validity of a potential personal ...
    (Date:7/25/2014)... Babies seem to learn even before they,re born, a ... 34 weeks pregnant, their unborn babies can respond to ... nursery rhyme, the researchers report. "The mother,s voice ... developing fetus," Charlene Krueger, nursing researcher and associate professor ... in a university news release. "This research highlights just ...
    Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2
    ... , MOUNTAIN VIEW, Calif., Nov. 20 Omnicell, Inc. (Nasdaq: ... announced today the company will present at the 21st Annual Piper ... NY. , Omnicell Speakers: Randall A. Lipps, founder, ... Date: Tuesday, December 1, 2009 , Time: 1:00 ...
    ... La., Nov. 20 The Louisiana ... experience higher health care premiums and reduced benefits if proposals ... Gil Dupre, chief executive officer for LAHP, "Louisiana health plans ... the national debate. Our plans have offered significant changes ...
    ... , WASHINGTON, Nov. 20 The Senate,s ... Act") infringes on Americans, health-insurance choices and medical privacy, ... Freedom (IHF) -- a patients, rights group in Washington, ... provisions): , Require nearly every legal resident to ...
    ... Calif., Nov. 20 Heritage Provider Network, and its founder, CEO ... 2009, Lakeside Medical Systems, Inc., as well as all its affiliated ... HPN family. , "We first and foremost want to assure all ... to maintaining the high level of care they are used to ...
    ... Nov. 20 Fear about the risk of surgery is ... aortic valve replacement surgery, according to a study by physicians ... this year, former First Lady Barbara Bush and comedian Robin ... be missing out on the potentially life-saving surgery. , In ...
    ... , NEW YORK, ... new market research report is available in ... Spending Benchmarks and Market Forecast to 2013 ... , Comprehensive Forecasts and Detailed Budget Benchmarks ...
    Cached Medicine News:Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2Health News:Senate Mandatory Health-Insurance Bill Infringes on Choice and Privacy 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 3Health News:Half of Eligible Patients Do Not Get Aortic Valve Replacement 2Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 2Health News:Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 3
    (Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
    (Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation ... conference call on Tuesday, August 5, 2014, at 8:30 ... second quarter 2014 financial results. An audio ... through the Investor Relations portion of the CVS Caremark ... visit http://info.cvscaremark.com/investors . This webcast will be archived ...
    (Date:7/25/2014)... 25, 2014  Acsis Inc., the market leader ... solutions, has recently posted an article, "Future ... and future needs for companies, extended supply chain, ... chain model no longer work today.  The article ... growth of mobile technology, machine to machine (M2M) ...
    Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2Acsis Addresses Questions on the Modern Supply Chain 2
    ... are specifically designed for PCR amplification ... fluorescence detection systems. The NGEN product ... of mutations associated with cystic fibrosis, ... as reagents for the detection of ...
    ... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
    ... specifically designed for PCR amplification and ... detection systems. The NGEN product line ... mutations associated with cystic fibrosis, thrombosis, ... reagents for the detection of sequences ...
    ... ICT is the latest and most advanced ... Hemoccult product line. An immunochemical FOBT (iFOBT) ... is clinically proven to detect bleeding associated ... guaiac-based FOBTs. Because of its superior specificity ...
    Medicine Products: